PRELIMINARY PROGRAM

Wednesday, November 5, 2025
WORKSHOP OPENING8:30 AM - 8:40 AM 
SESSION I8:40 AM - 10:10 AM
  • 08:40 a.m. - 09:00 a.m. New guidelines and re-thinking HBV nomenclature for therapeutic endpoints
  • 09:00 a.m. - 09:20 a.m. Will long acting NA's help our goals to achieve HBV cure or not?
  • 09:20 a.m. - 09:40 a.m. Real-world HBsAg levels and the impact HBsAg cut-offs for clinical trial enrollment
  • 09:40 a.m. - 10:10 a.m. Discussion
AM BREAK10:10 AM - 10:30 AM 
SESSION II10:30 AM - 12:00 PM
  • 10:30 a.m. - 10:50 a.m. Gene and Epigenome editing: what is the current knowledge on efficacy and risks?
  • 10:50 a.m. - 11:10 a.m. Advances in HDV treatment: Bulevirtide vs. mAb vs. small molecule, is there a front runner?
  • 11:10 a.m. - 11:30 a.m. Immune dysfunction vs. exhaustion - splitting hairs or real impact on immunotherapy
  • 11:30 a.m. - 12:00 p.m. Discussion
LUNCH BREAK12:00 PM - 1:00 PM 
SESSION III1:00 PM - 2:40 PM
  • 1:00 p.m. - 1:20 p.m. Translational immunology in oncology: a successful paradigm for cure studies?
  • 1:20 p.m. - 1:30 p.m. Efficacy of therapeutic vaccination with a novel checkpoint modifier.
  • 1:30 p.m. - 1:40 p.m. Leveraging prior vaccination to enhance functional cure rates in siRNA/IFN-α combination studies
  • 1:40 p.m. - 1:50 p.m. ImTAVs: Soluble, bi-specific T cell receptors to target HBsAg+ hepatocytes
  • 1:50 p.m. - 2:00 p.m. Anti-HBs monotherapy for HBV/HDV therapy.
  • 2:00 p.m. - 2:10 p.m. Anti-HBs combination therapies for treatment in HBV/HDV patients
  • 2:10 p.m. - 2:40 p.m. Discussion
PM BREAK2:40 PM - 3:10 PM 
SESSION IV3:10 PM - 4:55 PM
  • 3:10 p.m. - 3:30 p.m. Universal Standards for new HBV biomarkers to improve their utility.
  • 3:30 p.m. - 3:40 p.m. Evidence for durable HBsAg declines after long-term CAM therapies.
  • 3:40 p.m. - 3:50 p.m. RNA interference with ASO: Is functional cure sustained long-term?
  • 3:50 p.m. - 4:00 p.m. RNA interference with ASO: Latest results from new kid on the block.
  • 4:00 p.m. - 4:10 p.m. Bulevirtide + IFN-α in long-term treated HDV patients: optimal duration for sustained responses.
  • 4:10 p.m. - 4:25 p.m. Gene and epigenomic editing: early results in 3 elevator pitches.
  • 4:25 p.m. - 4:55 p.m. Discussion
CLOSING REMARKS4:55 PM - 5:00 PM 
NETWORKING RECEPTION5:00 PM - 7:00 PM 

*Subject to changes